Results 81 to 90 of about 23,498 (195)

Decoding the Pathophysiology of Autoimmune Diseases—Mechanism, Triggers, and Nanotherapeutics: A Review

Advanced NanoBiomed Research, Volume 6, Issue 4, April 2026.
This review highlights how autoimmune diseases arise from intertwined immunological, genetic, and environmental factors, emphasizing gut microbiota dysbiosis as a pivotal driver. It outlines emerging nanotechnology‐based strategies—such as liposomes, hydrogels, and polymeric nanoparticles—that enhance targeted drug delivery, minimize systemic toxicity,
Md. Meraj Ansari, Yunhui Min, Eun‐Ju Ko, Doyoung Kwon, Rehan Khan, Young‐Ok Son   +5 more
wiley   +1 more source

Immunological mechanism of action and clinical profile of disease-modifying treatments in multiple sclerosis. [PDF]

, 2014
Multiple sclerosis (MS) is a life-long, potentially debilitating disease of the central nervous system (CNS). MS is considered to be an immune-mediated disease, and the presence of autoreactive peripheral lymphocytes in CNS compartments is believed to be
A Compston, A Groves, A Kulakowska, A Miravalle, A Prat, A Shirani, AJ Coles, AL Cox, AM Palmer, B Balatoni, B Bielekova, BJ Oliver, C Boulton, C Brunmark, C Confavreux, C Saure, C Wegner, CH Polman, CL Mackall, D Azoulay, D Burger, D Cadavid, D Hunt, D Moharregh-Khiabani, D Moharregh-Khiabani, D Wynn, Daniel D. Pinschewer, DD Mikol, DD Pinschewer, DD Pinschewer, DD Pinschewer, DK Sato, Doron Merkler, DS Goodin, EM Frohman, F Martinelli Boneschi, F Rinaldi, F Santo Del, FD Lublin, G Bloomgren, G Comi, G Guarda, G Pilz, GA Kolumam, GM DeNicola, GP Rice, H Panitch, H Schmidt, HM Cherwinski, HP Hartung, I Metz, IL Tan, J Booss, J Chun, J Hanson, J Killestein, J Rio, JA Cohen, JA Cohen, JA Cohen, JC Lehmann, JF McDyer, JL McQualter, JR Berger, JS Yang, JW Choi, KA Brown, KA Buzzard, KB Walsh, KD Held, KJ Bayless, KP Johnson, L Durelli, L Kappos, L Kappos, L Klotz, LD Jacobs, LF Voort van der, LK Peterson, M Chen, M Gurevich, M Kala, M Mehling, M Mehling, M Meissner, M Prinz, M Skarica, M Vandermeeren, M Zeyda, MA Zarbin, MC Kraan, ME Kozovska, MJ Glennie, MK Racke, MM Vellinga, MQ Xia, MT Sweetser, N Koch-Henriksen, N Putzki, N Qizilbash, NS Roskell, O Fernandez, O Neuhaus, OJ Leger, P Kivisakk, P Maddison, P O’Connor, P O’Connor, P Vermersch, PS Sorensen, R Aspinall, R Deogracias, R Doorn van, R Gold, R Gold, R Milo, R Tanasescu, RA Bermel, RA Linker, RA Rudick, RC Selter, Renaud A. Du Pasquier, RH Scannevin, RJ Fox, S Dhib-Jalbut, S Jilek, S Marousi, S Nikfar, S Philipp, SC Steinberg, SJ Jackson, SK Manna, SP Morrissey, SR Mirandola, T Fujita, T Kuhlmann, T Ziemssen, TW West, TW West, V Brinkmann, V Brinkmann, V Parfenov, V Popescu, W Bruck, X Xu, X Xu   +145 more
core   +3 more sources

Review: Natalizumab in the treatment of multiple sclerosis

Therapeutic Advances in Neurological Disorders, 2009
Natalizumab reduced the rate of clinical relapse at one year by 68% and the risk of sustained progression of disability by 42—54% over 2 years in its pivotal phase III trial (AFFIRM) in relapsing—remitting multiple sclerosis (RRMS).
Özgür Yaldizli, Norman Putzki
doaj   +1 more source

Evolution of Drug Development Trends in Multiple Sclerosis: Analysis of Mainland China and Global Landscapes From 2004 to 2024

CNS Neuroscience &Therapeutics, Volume 32, Issue 4, April 2026.
This registry‐based analysis of 1183 MS clinical trials (2004–2024) shows sustained global activity and a marked increase in mainland China after 2018, predominantly driven by late‐phase and bioequivalence studies. Trial density varied across regions, and IFNAR, CD20, and S1PR1 were the most frequently investigated targets. ABSTRACT Background Multiple
Chaoyang Chen, Zhenyu Niu, Ting Yang, Xuanling Zhang, Ran Wei, Xiaocong Pang, Ran Liu, Ying Zhou   +7 more
wiley   +1 more source

EFFICIENT PROPAGATION OF ARCHETYPE JC POLYOMAVIRUS IN COS-7 CELLS: EVALUATION OF REARRANGEMENTS WITHIN NCCR STRUCTURAL ORGANIZATION DURING TRANSFECTION. [PDF]

, 2017
John Cunningham virus (JCPyV) is an ubiqui-tous human pathogen that causes disease in immunocom-promised patients. The JCPyV genome is composed of an early region and a late region, which are physically sepa-rated by the ...
Anzivino, Elena, Bellizzi, Anna, Palamara, ANNA TERESA, Pietropaolo, Valeria Antonietta, Prezioso, Carla, Rodio, DONATELLA MARIA, Scribano, D, Trancassini, Maria   +7 more
core   +1 more source

Presymptomatic diagnosis with MRI and adequate treatment ameliorate the outcome after natalizumab-associated progressive multifocal leukoencephalopathy (PML).

Frontiers in Neurology, 2013
Natalizumab (Tysabri®) is a monoclonal antibody that prevents inflammatory cells from binding to brain endothelial cells and passing into the brain parenchyma.
Hans eLindå, Anders evon Heijne
doaj   +1 more source

Acute Cryptococcal Immune Reconstitution Inflammatory Syndrome in a Patient on Natalizumab [PDF]

, 2016
Presented is the first case of acute immune reconstitution inflammatory syndrome (IRIS)-associated cryptococcal meningoencephalitis in a patient on natalizumab for multiple sclerosis.
Drwiega, Joseph C., Gundacker, Nathan D., Jones, Benjamin A., Jordan, Stephen J., Pappas, Peter G.   +4 more
core   +3 more sources

A comparative study of fatigue and processing speed in patients with multiple sclerosis treated with natalizumab or rituximab

Multiple Sclerosis Journal - Experimental, Translational and Clinical
Background Fatigue is the most debilitating symptom in patients with multiple sclerosis (MS). Natalizumab and rituximab are the most used MS disease modifying therapies in Sweden, but comparative data on the effect on fatigue is sparse. Objective Primary
Johan Hellgren, Maria Compagno Strandberg, Kristina Källén, Anders Svenningsson   +3 more
doaj   +1 more source

Changes in JC virus-specific T cell responses during natalizumab treatment and in natalizumab-associated progressive multifocal leukoencephalopathy.

PLoS Pathogens, 2012
Progressive multifocal leukoencephalopathy (PML) induced by JC virus (JCV) is a risk for natalizumab-treated multiple sclerosis (MS) patients. Here we characterize the JCV-specific T cell responses in healthy donors and natalizumab-treated MS patients to
Molly R Perkins, Caroline Ryschkewitsch, Julia C Liebner, Maria Chiara G Monaco, Danielle Himelfarb, Sara Ireland, Annelys Roque, Heather L Edward, Peter N Jensen, Gina Remington, Thomas Abraham, Jaspreet Abraham, Benjamin Greenberg, Charles Kaufman, Chris LaGanke, Nancy L Monson, Xiaoning Xu, Elliot Frohman, Eugene O Major, Daniel C Douek   +19 more
doaj   +1 more source

Explaining temporal trends in annualized relapse rates in placebo groups of randomized controlled trials in relapsing multiple sclerosis: systematic review and meta-regression

, 2013
Background: Recent studies have shown a decrease in annualised relapse rates (ARRs) in placebo groups of randomised controlled trials (RCTs) in relapsing multiple sclerosis (RMS).
Friede, Tim, Nicholas, Richard, Röver, Christian, Schneider, Simon, Steinvorth, Simon M., Straube, Sebastian   +5 more
core   +1 more source